Fracture healing is a complex process of many coordinated biological pathways. This system can go awry resulting in nonunion, which leads to significant patient morbidity. The Hedgehog (Hh) signaling pathway is upregulated in fracture healing. We hypothesized that the Hh signaling pathway can be pharmacologically modulated to positively affect fracture healing. Diaphyseal femur fractures were created in elderly mice (18 months, C57BL/6 females), which have a blunted and delayed healing response compared to younger mice, and were stabilized with intramedullary pins. To activate the Hh pathway we targeted the receptor Smoothened using an agonist (Hh-Ag1.5 [Hh-Ag]) and compared this to a vehicle control. Expression of Hh target genes were significantly increased in the fracture callus of the agonist group compared to controls, indicating pathway activation. Expression of osteogenic and chondrogenic-related genes was greatly upregulated in fracture callus vs. intact femora, although Hh agonist treatment did not consistently enhance this response. Blindly graded, radiographic callus healing scores were significantly higher in the Hh-Ag groups at post operative day (POD) 14, indicating earlier callus bridging. On microCT, Hh-Ag treatment led to greater callus volume (+40%) and bone volume (+25%) at POD21. By day 14, callus vascularity, as assessed by 3D microCT angiography vessel volume, was 85% greater in the Hh-Ag group. Finally, mechanical strength of the calluses in the Hh-Ag groups was significantly greater than in the control groups at POD21. In conclusion, systemic administration of a Hh agonist appears to improve the osseous and vascular healing responses in a mouse fracture healing-impaired model.

Fracture healing recapitulates many aspects of developmental osteogenesis. The hedgehog (Hh) signaling pathway, essential to skeletal development, is upregulated during fracture healing, although its importance is unclear. Our goal was to assess the functional importance of Hh signaling in endochondral fracture healing. We created closed, transverse diaphyseal femur fractures in mice, stabilized with an intramedullary pin, and administered a systemic Hh inhibitor or vehicle. Because Hh pathway activation is mediated by the receptor Smoothened (Smo), we used the Smo antagonist GDC-0449 (GDC, 50 mg/kg, twice daily) to target the pathway. First, in vehicle-treated 10-wk female C57BL/6 mice we confirmed that Hh signaling was increased in fracture callus compared to intact bone, with >5-fold upregulation of target genes Ptch1 and Gli1. Additionally, using 10-wk male and female Gli1 reporter mice, we saw a strong activation of the reporter in the osseous regions of the fracture callus 7–10 days after fracture. GDC treatment significantly blunted these responses, indicating effective inhibition of fracture-induced Hh signaling in bone. Moreover, microCT analysis revealed that GDC treatment significantly reduced cancellous and cortical bone volume at non-fracture sites (tibial metaphysis and diaphysis), suggesting that the drug inhibited normal bone formation. GDC treatment had a modest effect on fracture healing, with evidence of delayed callus mineralization radiographically (significantly lower Goldberg score at day 14) and by microCT (reduced callus vBMD at 14 days), and a delay in the recovery of torsional rotation to normal (elevated rotation-at-peak torque at 21 days). On the other hand, GDC treatment did not inhibit qPCR or morphological measures of chondrogenesis or angiogenesis, and did not impair the recovery of failure torque (at day 14 or 21), a measure of biomechanical competence. In summary, GDC treatment inhibited Hh signaling, which delayed but did not prevent fracture healing in young mice. We conclude that Hh signaling is strongly induced after fracture and may play a role in early callus mineralization, although it does not appear to be required for eventual healing.

Cleft widths from the lip through to the posterior hard palate are generally greater in children who are diagnosed with Class III occlusion later in life. Notably, the alveolar cleft width is significantly greater at each time point for patients who went on to develop Class III occlusion. There were no significant differences in cleft widths between patients diagnosed later with Class I and Class II occlusions.

Background: Fixation of distal femur fractures with lateral locking plates has relatively high rates of clinical failure. Supplemental fixation has shown promising results, and may reduce rates of fixation failure or nonunion. This review aimed to assess the biomechanical and clinical evidence regarding the use of supplemental fixation of distal femur fractures. Methods: PubMed, Embase, and Cochrane databases were searched for English language studies up to December 4, 2020, identifying 1,829 studies. Biomechanical studies that assessed fracture displacement, load/cycles to failure, or construct stiffness and clinical studies that assessed fixation failure or nonunion after supplemental fixation of distal femur fractures were included. Studies with sample size ≤5, ORIF with non-locking plates, periprosthetic distal femoral fractures, nonunions or revision surgeries were excluded. Results: Seventeen studies were included, of which 8 were biomechanical and 9 clinical. Overall, biomechanical studies demonstrated increased construct stability and load to failure with various supplemental fixation strategies. Clinical studies demonstrated more mixed outcomes for nonunion and fixation failure rate among the various techniques. Conclusions: Biomechanical studies have demonstrated potential benefits of these strategies, but there remains a dearth of high-quality evidence evaluating their effect on clinical outcomes. Prospective RCTs are necessary to address these issues and confirm the results in the existing literature. Level of Evidence: IID